Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 1999;84:1156-1165

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, Y.
Right arrow Articles by Ashraf, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, Y.
Right arrow Articles by Ashraf, M.
Related Collections
Right arrow Cell biology/structural biology
Right arrow Cell signalling/signal transduction
Right arrow Ion channels/membrane transport
(Circulation Research. 1999;84:1156-1165.)
© 1999 American Heart Association, Inc.


Original Contribution

Role of Protein Kinase C in Mitochondrial KATP Channel–Mediated Protection Against Ca2+ Overload Injury in Rat Myocardium

Yigang Wang, Muhammad Ashraf

From the Department of Pathology and Laboratory Medicine, University of Cincinnati Medical Center, Ohio.

Correspondence to Muhammad Ashraf, PhD, Department of Pathology and Laboratory Medicine, University of Cincinnati Medical Center, 231 Bethesda Ave, Cincinnati, OH 45267-0529.


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMaterials and Methods
down arrowMeasurement of LDH
down arrowMeasurement of Tissue ATP
down arrowImmunofluorescence Microscopy
down arrowMorphological Examination
down arrowStatistical Analysis
down arrowResults
down arrowDiscussion
down arrowReferences
 
Abstract—Growing evidence exists that ATP-sensitive mitochondrial potassium channels (MitoKATP channel) are a major contributor to the cardiac protection against ischemia. Given the importance of mitochondria in the cardiac cell, we tested whether the potent and specific opener of the MitoKATP channel diazoxide attenuates the lethal injury associated with Ca2+overload. The specific aims of this study were to test whether protection by diazoxide is mediated by MitoKATP channels; whether diazoxide mimics the effects of Ca2+ preconditioning; and whether diazoxide reduces Ca2+ paradox (PD) injury via protein kinase C (PKC) signaling pathways. Langendorff-perfused rat hearts were subjected to the Ca2+ PD (10 minutes of Ca2+ depletion followed by 10 minutes of Ca2+ repletion). The effects of the MitoKATP channel and other interventions on functional, biochemical, and pathological changes in hearts subjected to Ca2+ PD were assessed. In hearts treated with 80 µmol/L diazoxide, left ventricular end-diastolic pressure and coronary flow were significantly preserved after Ca2+ PD; peak lactate dehydrogenase release was also significantly decreased, although ATP content was less depleted. The cellular structures were well preserved, including mitochondria and intercalated disks in diazoxide-treated hearts compared with nontreated Ca2+ PD hearts. The salutary effects of diazoxide on the Ca2+ PD injury were similar to those in hearts that underwent Ca2+ preconditioning or pretreatment with phorbol 12-myristate 13-acetate before Ca2+ PD. The addition of sodium 5-hydroxydecanoate, a specific MitoKATP channel inhibitor, or chelerythrine chloride, a PKC inhibitor, during diazoxide pretreatment completely abolished the beneficial effects of diazoxide on the Ca2+ PD. Blockade of Ca2+ entry during diazoxide treatment by inhibiting L-type Ca2+ channel with verapamil or nifedipine also completely reversed the beneficial effects of diazoxide on the Ca2+ PD. PKC-{delta} was translocated to the mitochondria, intercalated disks, and nuclei of myocytes in diazoxide-pretreated hearts, and PKC-{alpha} and PKC-{epsilon} were translocated to sarcolemma and intercalated disks, respectively. This study suggests that the effect of the MitoKATP channel is mediated by PKC-mediated signaling pathway.


Key Words: K+ channel • Ca2+ paradox • Ca2+ preconditioning • protein kinase C • diazoxide


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMaterials and Methods
down arrowMeasurement of LDH
down arrowMeasurement of Tissue ATP
down arrowImmunofluorescence Microscopy
down arrowMorphological Examination
down arrowStatistical Analysis
down arrowResults
down arrowDiscussion
down arrowReferences
 
Massive cell damage occurs in the heart within seconds when it is perfused with perfusate devoid of Ca2+ followed by perfusion with a solution that contains Ca2+. This phenomenon has been called the Ca2+ paradox (Ca2+ PD). The common features of the Ca2+ PD are Ca2+ overload, sarcolemmal destruction, necrosis of the cell, depletion of high-energy phosphates, and loss of intracellular contents.1 2 Mechanisms by which Ca2+ PD induces cell injury include altered Ca2+ channels, damaged cell membranes, disrupted intercalated disks, impaired Na+-Ca2+ exchange, disruptive mechanical forces, and oxidative stress.3 4 5 6

To understand these mechanisms, we plan to use the reverse strategy of testing interventions to discover cellular pathways that lead to reduction of Ca2+ PD injury. A mild stress induced by brief Ca2+ depletion and repletion, called Ca2+ preconditioning,2 has been shown to protect the myocardium from Ca2+ PD injury or subsequent sustained ischemia/reperfusion.7 Protein kinase C (PKC) was shown to be a major component in the attenuation of cell injury caused by Ca2+ preconditioning (CPC). Recent evidence suggests that the MitoKATP channel is mainly involved in preconditioning against ischemia/reperfusion.8 9 Garlid and his colleagues 10 reported that the KATP channel from cardiac mitochondria is 2000 times more sensitive to diazoxide than the sarcolemmal channel, which indicates that 2 distinct channel subtypes coexist within the myocyte. Liu and colleagues 9 also reported that diazoxide targets mitochondrial but not sarcolemmal KATP channels. We have previously shown that CPC elicits its protection through PKC–mediated signaling pathways.7 Therefore, it appears that the effects of both PKC and the MitoKATP channel are interlinked. Accordingly, we hypothesize that diazoxide opens both MitoKATP channels and activates PKC. The results of this study show that the participation of PKC is essential in MitoKATP channel–mediated cardiac protection.


*    Materials and Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Materials and Methods
down arrowMeasurement of LDH
down arrowMeasurement of Tissue ATP
down arrowImmunofluorescence Microscopy
down arrowMorphological Examination
down arrowStatistical Analysis
down arrowResults
down arrowDiscussion
down arrowReferences
 
Materials
Diazoxide, phorbol 12-myristate 13-acetate (PMA), and chelerythrine chloride were purchased from Sigma Chemical Co. Verapamil hydrochloride was purchased from Research Biochemicals International. Sodium 5-hydroxydecanoate (5-HD) was purchased from ICN Pharmaceuticals, Inc. OCT compound was from Miles Laboratories; Rabbit polyclonal isoform–specific anti-PKC antibodies were purchased from Santa Cruz Biotechnology Inc. These antibodies were raised against isoform-unique peptide sequences within the carboxy terminus ({alpha}, 651 to 672; ßI, 656 to 671; ßII, 657 to 673; {gamma}, 679 to 697; {delta}, 657 to 673; {epsilon}, 722 to 736; {eta}, 669 to 683; and {zeta}, 573 to 592). Indocarbocyanine-conjugated anti-rabbit IgG antibody was purchased from Jackson ImmunoResearch Laboratories, Inc. PMA and diazoxide were dissolved in DMSO before being added into the perfusion buffer. The final concentration of DMSO was <0.1%. Other reagents were dissolved in PBS. All the agents except diazoxide and PMA were directly administered through the aortic cannula at a rate of 0.2 mL/min by use of a Harvard infusion pump.

Heart Preparation
The current study conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH, Publication No. 85–23, revised 1985). Male Sprague-Dawley rats that weighed 250 to 300 g were anesthetized by an intraperitoneal injection of 30 mg/kg pentobarbital. After intraperitoneal injection of 500 U/kg heparin sodium, hearts were removed and retrogradely perfused through the aorta in a noncirculating Langendorff apparatus with Krebs-Henseleit (KH) buffer, which consisted of the following (mmol/L): NaCl 118, KCl 4.7, MgSO4 1.2, KH2PO4 1.2, CaCl2 1.8, NaHCO3 25, and glucose 11. The buffer was saturated with 95% O2/5% CO2 (pH 7.4, 37°C) for 50 minutes. Hearts were perfused at a constant pressure of 80 mm Hg. A water-filled latex balloon–tipped catheter was inserted into the left ventricle through the left atrium and was adjusted to a left ventricular end-diastolic pressure (LVEDP) of 4 to 6 mm Hg during the initial equilibration. Thereafter, the balloon volume was not changed. The distal end of the catheter was connected to a heart performance analyzer (Digi-Med model 210, version 1.01, Micro-Med) via a pressure transducer. Hearts were paced at 350 bpm except during periods of Ca2+ depletion in all groups. The index of myocardial function was determined with left ventricular developed pressure, which was calculated from the difference between left ventricular peak systolic pressure and end-diastolic pressure. Left ventricular systolic pressure, end-diastolic pressure, and the derivative of left ventricular pressure (±dP/dt) were recorded continuously as a function of time by personal computer (International Computer Technology, Inc). After perfusion with the oxygenated KH buffer for an equilibration period of 25 minutes, a 3-way stopcock above the aortic root was used to perfuse the Ca2+-free KH buffer for 10 minutes, followed by a KH buffer that contained Ca2+ for 10 minutes, to induce a typical Ca2+ PD.2 The coronary effluent was collected in a beaker, and the coronary flow was determined volumetrically at the pretreatment; just before being subjected to Ca2+ depletion; during the Ca2+ depletion period; and at 1, 3, 5, and 10 minutes during Ca2+ repletion.

Experimental Protocol
After equilibration, hearts were randomly divided into experimental groups.

Group 1: Normal Control and Vehicle Control
Hearts (n=6) were perfused for 45 minutes with KH buffer as a normal control for different experimental groups. Rat hearts were pretreated for 6 minutes with vehicle (0.01% DMSO, n=6) followed by a 5-minute washout, after which the hearts were subjected to the Ca2+ PD. The amounts of DMSO used in vehicle control experiments did not affect any hemodynamic parameters, lactate dehydrogenase (LDH) release, ATP content, or cell morphology (data not shown).

Group 2: Ca2+ PD
After a 25-minute perfusion with normal KH buffer, hearts (n=8) were subjected to Ca2+-free KH buffer for 10 minutes followed by KH buffer that contained Ca2+ for 10 minutes.

Group 3A: Ca2+ Preconditioning and Calcium Paradox
This group was designed to determine whether CPC elicits protection against Ca2+ PD. Hearts (n=8) were perfused for 3 cycles of 1 minute each with Ca2+-free KH buffer followed by 5 minutes with Ca2+-containing KH buffer; then, the hearts were subjected to Ca2+ PD as in group 2.

Group 3B: 5-HD, CPC, and Ca2+ PD
The rationale for this experiment was that CPC activates MitoKATP channels, which results in attenuation of cellular injury. To test this, 5-HD, a specific blocker of MitoKATP channels, was used during CPC.

Hearts (n=8) were perfused in a manner similar to that used for group 3A, except that 5-HD (100 µmol/L) was infused for 4 minutes before CPC. The dose of 5-HD was chosen on the basis of a previous report.8

Group 3C: Chelerythrine Chloride, CPC, and Ca2+ PD
This group tested whether the inhibition of PKC during CPC also abrogates the protection. Chelerythrine chloride was added instead of 5-HD. Hearts (n=8) were perfused in a manner similar to that used in group 3A, except that chelerythrine chloride (6.4 µmol/L), a specific PKC inhibitor, was infused through the aorta at a rate of 0.2 mL/min for 4 minutes before CPC. The dose of chelerythrine chloride was chosen on the basis of a previous report.7

Group 4: Role of MitoKATP Channels in Cardiac Protection
Diazoxide, a potent opener of the MitoKATP channel, was used during Ca2+ PD. Diazoxide opens the sarcolemmal KATP channel at a higher concentration (855 µmol/L=K 1/2), whereas it opens the MitoKATP channel at a low concentration (0.4 µmol/L=K 1/2).10 This group will determine whether this specific opener of MitoKATP channels mimics the effect of CPC. An inhibitor of mitochondrial KATP channels 5-HD was used to determine whether MitoKATP channels play an important role in the prevention of cell injury. It has been reported that 5-HD abolishes the protective effects of KATP channel openers, although it has no effect on the ADP-shortening activity, which suggests its high specificity for MitoKATP channels.11

Group 4A: Diazoxide and Ca2+ PD
Hearts were perfused with KH buffer that contained diazoxide for 6 minutes and then washed out for 5 minutes. After the hearts were washed, they were subjected to the Ca2+ PD. A dose response of diazoxide with 1, 30, 40, 80, and 100 µmol/L was studied (n=6 to 10 hearts for each subgroup). We found 80 µmol/L diazoxide to have the optimal effect on the Ca2+ PD injury.

Group 4B: 5-HD, Diazoxide, and Ca2+ PD
Hearts (n=8) were perfused similarly to group 4A except 5-HD (100 µmol/L) was infused before the use of diazoxide.

Group 5: Influence of PKC on MitoKATP Channel
To determine whether the direct activation of PKC protects the myocardium independent of MitoKATP channels, we used the PKC activator PMA.

Group 5A: PMA and Ca2+ PD
Hearts (n=8) were perfused with KH buffer that contained PMA (100 nmol/L) for 6 minutes followed by a 5-minute washout before the Ca2+ PD. The dose of PMA was chosen on the basis of a previous report.11

Group 5B: Chelerythrine Chloride, Diazoxide, and Ca2+ PD
To determine whether diazoxide activates MitoKATP channels via a PKC signaling pathway, hearts (n=8) were perfused by a method similar to group 4A except chelerythrine chloride (6.4 µmol/L) was infused through the aorta at the rate of 0.2 mL/min for 4 minutes before diazoxide was added.

Group 6: Verapamil or Nifedipine, Diazoxide, and Ca2+ PD
These experiments tested the hypothesis that diazoxide is linked to transient Ca2+ increase, which was responsible for the cardioprotection available through the PKC signaling pathway. The Ca2+ entry was blocked by verapamil or nifedipine, which are both L-type Ca2+ channel blockers.

This group was similar to group 4A except that verapamil (2 µmol/L) or nifedipine (0.001 µmol/L) was infused at a rate of 0.2 mL/min for 4 minutes before diazoxide administration (n=6 to 8). After a 5-minute washout, Ca2+ PD was instituted. The doses of verapamil and nifedipine were chosen on the basis of a previous report.12 13


*    Measurement of LDH
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
*Measurement of LDH
down arrowMeasurement of Tissue ATP
down arrowImmunofluorescence Microscopy
down arrowMorphological Examination
down arrowStatistical Analysis
down arrowResults
down arrowDiscussion
down arrowReferences
 
LDH, an indicator of myocardial tissue injury, was determined in coronary effluent2 by a coupled-enzyme spectrometric technique by use of a Sigma assay kit. Measurement of enzyme activity was based on the oxidation of lactate and the rate of increase in absorbance at 340 nm.


*    Measurement of Tissue ATP
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowMeasurement of LDH
*Measurement of Tissue ATP
down arrowImmunofluorescence Microscopy
down arrowMorphological Examination
down arrowStatistical Analysis
down arrowResults
down arrowDiscussion
down arrowReferences
 
After termination of the experiment, hearts were cut into transverse slices and immediately frozen in liquid nitrogen until they were freeze-dried. Fifty to 100 mg of freeze-dried tissue was crushed in a precooled glass tube, and ATP was extracted with 5 mL of cold 6% trichloroacetic acid. The extract was analyzed for ATP by the spectrophotometric method.2


*    Immunofluorescence Microscopy
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowMeasurement of LDH
up arrowMeasurement of Tissue ATP
*Immunofluorescence Microscopy
down arrowMorphological Examination
down arrowStatistical Analysis
down arrowResults
down arrowDiscussion
down arrowReferences
 
Subcellular localization of PKC isoforms after various interventions were performed by immunofluorescence staining and were compared with control hearts as previously described.12 14 Control and specimens with previous treatments were harvested just before Ca2+ depletion. Left ventricular tissue was blotted and embedded in OCT compound, rapidly frozen in liquid nitrogen, and then stored at -70°C until use.15 Transverse 5-µm cryosections were prepared with a cryostat (Jung Frigocut 2800E, Leica) and collected on poly-L-lysine–coated slides. All sections were fixed for 10 minutes in a 70% acetone/30% methanol mixture at -20°C, rinsed in PBS, and incubated in 10% normal goat serum in PBS for 30 minutes to block nonspecific binding. Primary antibodies (rabbit polyclonal antibodies against PKC isoforms PKC-{alpha}, PKC-ßI, PKC-ßII, PKC-{gamma}, PKC-{delta}, PKC-{epsilon}, PKC-{eta}, and PKC-{zeta}) were diluted with PBS that contained 0.1% BSA. Sections were incubated for 1 hour at room temperature with diluted primary antibodies and then washed with PBS 3 times (3 minutes each). Sections were then incubated for 45 minutes with indocarbocyanine-conjugated goat anti-rabbit IgG, then washed once with 0.1% Triton X-100 in PBS for 3 minutes, and washed twice with PBS (2 minutes each). Nuclear staining was achieved with bis-benzamide (10 mg/mL in PBS) for 30 seconds and washed with PBS 3 times (2 minutes each). Sections were mounted with a medium (Antifade, Oncor) and were examined and photographed with a microscope equipped with fluorescence optics (BH-2 with a PM-CBSP camera, Olympus). Confocal images were also obtained with a Leitz DME fluorescence microscope with a TCS 4D confocal scanning attachment (Leica, Inc). Fluorescence was excited by the 568-nm line of krypton laser, and the emission was recorded at 568 to 580 nm.


*    Morphological Examination
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowMeasurement of LDH
up arrowMeasurement of Tissue ATP
up arrowImmunofluorescence Microscopy
*Morphological Examination
down arrowStatistical Analysis
down arrowResults
down arrowDiscussion
down arrowReferences
 
Heart tissue was taken from the left ventricular free wall at the end of experimental protocols and was cut into 1.0-mm pieces that were fixed with 2.5% buffered glutaraldehyde. A semiquantitative estimate of cell damage was performed on 1-µm-thick sections. Three randomly chosen blocks from each heart were examined for quantification of cell damage without prior knowledge of the treatment. Approximately 500 cells were analyzed in each heart, and 1 of 3 degrees of cell damage was assigned to each cell. Cell morphology was assessed according to the following classification2 15 : (1) normal: compact myofibers with uniform staining of nucleoplasm, well-defined rows of mitochondria between the myofibrils, and nonseparation of opposing intercalated disks; (2) mild damage: same as above, except some vacuoles were present adjacent to the mitochondria; and (3) severe damage: reduced staining of cytoplasmic organelles, clumped chromatin material, wavy myofibers, and granularity of cytoplasm; the cells with contraction band necrosis were added to this category.


*    Statistical Analysis
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowMeasurement of LDH
up arrowMeasurement of Tissue ATP
up arrowImmunofluorescence Microscopy
up arrowMorphological Examination
*Statistical Analysis
down arrowResults
down arrowDiscussion
down arrowReferences
 
All values are expressed as mean±SEM. Group comparisons were done by ANOVA (Statview 4.0.). All groups were analyzed simultaneously with the Bonferroni-Dunn test. A difference of P<0.05 was considered significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowMeasurement of LDH
up arrowMeasurement of Tissue ATP
up arrowImmunofluorescence Microscopy
up arrowMorphological Examination
up arrowStatistical Analysis
*Results
down arrowDiscussion
down arrowReferences
 
Ca2+ Paradox
During Ca2+ PD, hearts were bleached of normal reddish color, which indicated the loss of intracellular contents. Then the hearts underwent severe contracture and lost their contractile function (Table 1Down). At the end of the Ca2+-free period, LDH release was not different than the normal control values. Immediately on Ca2+ repletion, LDH release increased multifold and peaked after 3 minutes of Ca2+ repletion (Figure 1Down). Similarly, the maximum LDH release was also observed in Ca2+ PD hearts versus other groups (Figure 1Down). Coronary flow was significantly reduced at the end of Ca2+ PD (Table 1Down). Tissue ATP content in Ca2+ PD hearts was obviously depleted compared with the control hearts (Figure 2Down). In Ca2+ PD hearts, most of the cells were hypercontracted, and the cell membranes were ruptured, which resulted in the loss of mitochondria, myoglobin, and other cellular proteins (Figure 3BDown, Table 2Down). After a 10-minute period of Ca2+-free perfusion, tissue showed increased interfibrillar space and a marked separation in region of the intercalated disks in hearts treated without diazoxide (Figure 3LDown).


View this table:
[in this window]
[in a new window]
 
Table 1. Effect of Various Interventions on Hemodynamic Parameters in Hearts Subjected to Ca2+ PD



View larger version (36K):
[in this window]
[in a new window]
 
Figure 1. Effect of various interventions on temporal LDH release.



View larger version (27K):
[in this window]
[in a new window]
 
Figure 2. Effect of various interventions on ATP contents in hearts subjected to Ca2+ PD.



View larger version (110K):
[in this window]
[in a new window]
 
Figure 3. Effect of different interventions on the cell morphology. A, Normal heart. Nuclei showed uniform distribution of chromatin material (arrowhead). Compact and well-preserved myofibers were observed (x400). B, Ca2+ PD heart. All cells were so hypercontracted that the membranes were ruptured. As a result, mitochondria were extruded from the cells (arrowhead; x400). C, Heart treated with CPC. Most of myocytes were well preserved with the exception of some damaged cells (arrowhead; x400). D, Heart treated with 5-HD and CPC. All myocytes were severely damaged (x400). E, Heart treated with chelerythrine (CHE) and CPC. All myocytes were severely damaged (x400). F, Diazoxide (DE)-pretreated heart. Myocytes were significantly preserved compared with nontreated calcium paradox heart (B). A few damaged cells were also observed (arrowhead; x400). G, Heart treated with DE and 5-HD. All cells were damaged similar to Ca2+ PD (x400). H, Heart treated with DE and CHE. All cells were damaged as with the Ca2+ PD (x400). I, PMA-pretreated heart. Most of myocytes were well preserved, with the exception of some damaged cells (arrowhead; x400). J, Heart treated with DE and verapamil (VL). All cells were damaged similarly to the Ca2+ PD (x400). K, Heart treated with DE. After a 10-minute period of Ca2+-free perfusion, the separation of the intercalated disk is rarely seen (arrowhead; x400). L, After a 10-minute period of Ca2+-free perfusion without DE, a marked separation in the region of the intercalated disk is frequently observed (arrowhead; x400).


View this table:
[in this window]
[in a new window]
 
Table 2. Semiquatitative Estimate of Morphological Damage in Hearts Subjected to Ca2+ PD After Various Interventions

Effects of MitoKATP Channel and PKC and Ca2+ Preconditioning on Ca2+ PD
Intracellular ATP was preserved in diazoxide-treated hearts (Figure 2Up). However, no significant differences existed in LDH release and tissue ATP levels between diazoxide- and CPC-treated hearts after Ca2+ repletion. After Ca2+ repletion, most of the hearts pretreated with PMA, CPC, or diazoxide exhibited a weak beat. In diazoxide- or CPC-treated hearts, maximum LDH release was reduced significantly (P<0.05) compared with Ca2+ PD hearts (Figure 1Up).

At the end of Ca2+ repletion, a significant improvement in coronary flow and LVEDP was observed in diazoxide-treated, PMA-treated, and CPC hearts versus hearts subjected to Ca2+ PD alone. The cellular structure was also markedly preserved in the diazoxide-treated and CPC hearts. In diazoxide-pretreated hearts, 49.3% of cells were normal and 17.4% and 33.3% were mildly and severely damaged, respectively (Table 2Up). After a 10-minute period of Ca2+-free perfusion, tissue showed considerable separation of cells at the intercalated disks. This separation of the intercalated disks in diazoxide-pretreated hearts was at a lower scale (Figure 3KUp) than that in control Ca2+ PD hearts.

In a separate series of experiments, we determined the effect of the 5-HD on the cardiac protection elicited by CPC. The hearts treated with 5-HD during CPC stopped beating. In chelerythrine-treated hearts during CPC, LVEDP and LDH release were significantly increased and CF and tissue ATP levels were similar to those of the Ca2+ PD group (Table 1Up, Figures 1Up and 2Up). Similarly, during CPC, 5-HD–treated hearts underwent drastic morphological changes (Table 2Up, Figure 3Up). Similarly, the blockade of MitoKATP channels with 5-HD during diazoxide treatment caused a loss of contractile function during Ca2+ repletion.

Effect of Diazoxide on PKC Activation
To determine whether MitoKATP channel opening by diazoxide is mediated via PKC signaling pathways, hearts were pretreated with chelerythrine. The contractile function in hearts treated with chelerythrine and diazoxide was lost. LVEDP, maximum LDH release, coronary flow, and tissue ATP levels were similar to the Ca2+ PD group (Table 1Up, Figures 1Up and 2Up). Morphological damage was also significantly higher in hearts pretreated with chelerythrine (Table 2Up, Figure 3Up).

Diazoxide and Blockade of L-Type Ca2+ Channel
To determine whether a transient increase in [Ca2+]i during diazoxide infusion triggers cardioprotection, we attempted to reduce Ca2+ entry during diazoxide treatment. The protective effect of diazoxide was abolished in hearts pretreated with verapamil or nifedipine (Table 1Up). Maximum LDH release was significantly higher, and loss of tissue ATP content was similar to nontreated hearts (Figures 1Up and 2Up). In separate experiments, the hearts treated with only verapamil or nifedipine did not exhibit any beneficial effects (data not shown).

Immunocytochemical Distribution of PKC Isoforms After Various Interventions
Representative results from the immunohistochemical study are shown in Figure 4Down. PKC-{alpha}, which was diffusely distributed in the cytoplasm of cells in control, was distinctly localized in the cardiac cell sarcolemma. PKC-{delta} was positively localized in the mitochondrial sites, intercalated disks, and nuclei of myocytes in diazoxide-treated hearts. PKC-{epsilon} was localized in the intercalated disks of >90% of cells in diazoxide-pretreated hearts. PKC-ßI staining was observed in the nuclear region. PKC-{delta}, PKC-{alpha}, PKC-{epsilon}, and PKC-ßI showed diffuse nonspecific immunofluorescence in heart treated with 5-HD, chelerythrine, or verapamil during diazoxide-pretreatment, respectively. (Only PKC-{delta} isoforms were shown in hearts treated with 5-HD, chelerythrine, or verapamil, respectively, during diazoxide-pretreatment.) Staining with PKC-ßII, PKC-{gamma}, PKC-{eta}, and PKC-{zeta} was less intense and weaker than with PKC-{alpha}, -{delta}, -{epsilon} and -ßI isoforms after diazoxide treatment.



View larger version (122K):
[in this window]
[in a new window]
 
Figure 4. Immunofluorescent staining of PKC isoforms. A, Negative control (no PKC antibody). B, PKC-{alpha} in control hearts. Diffuse cytoplasmic distribution of the {alpha} isoform is observed. C, PKC-{alpha} in a DE-treated heart. Immunofluorescence is observed in the sarcolemma (arrow). D, PKC-{delta} in DE-treated heart. PKC-{delta} is positively localized in the mitochondrial sites between myofibers (arrow), intercalated disks (arrowhead), and nuclei (not shown). PKC-{delta} in control hearts is similar to panel B (data not shown). E, PKC-{delta} in heart treated with DE and 5-HD. A diffuse and nonspecific immunofluorescence is observed. F, PKC-{delta} in hearts treated with DE and CHE; no specific localization is observed. G, PKC-{delta} in hearts treated with DE and VL; no specific localization is observed. H, PKC-{epsilon} in DE-treated heart; PKC-{epsilon} is prominently distributed in the intercalated disks (arrow). PKC-{epsilon} in control hearts is similar to panel B (data not shown). I, PKC-ßI staining was observed in the nuclear region (arrow). All magnifications x400 except confocal imaging, which is 630x1.4. Micrographs in panels C, D, H, and I were taken with a confocal microscope, and others were taken with an immunofluorescent microscope.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowMeasurement of LDH
up arrowMeasurement of Tissue ATP
up arrowImmunofluorescence Microscopy
up arrowMorphological Examination
up arrowStatistical Analysis
up arrowResults
*Discussion
down arrowReferences
 
The main findings of the present study are as follows: (1) MitoKATP channel is the effector of Ca2+ preconditioning. (2) The protective effect caused by MitoKATP channel activation is mediated by PKC signaling pathways. (3) Diazoxide effect is blocked by verapamil or nifedipine, inhibitors of L-type Ca2+ channels. (4) Translocation of PKC-{alpha} to the cell membrane and PKC-{delta} to the mitochondrial sites was dominant, although PKC-ßI and PKC-{epsilon} were distributed in the nuclear region and intercalated disks, respectively, in diazoxide-pretreated hearts.

Role of the Diazoxide on Cardioprotection
The activation of the sarcolemmal KATP channel shortens the action potential duration subsequent to increased K+ efflux and decreased Ca2+ influx via voltage-gated channels, which leads to attenuation of cellular damage during ischemia.16 However, several studies from other laboratories showed a poor correlation between sarcolemmal K+ currents and cardioprotection by ATP-sensitive K+ channel openers (KCOs).8 Recognition of the MitoKATP channel as an intracellular receptor for KCOs adds a new dimension to the KCO pharmacology.10 Recently, the MitoKATP channel has been proposed as the site of cardioprotective action.17 Diazoxide is reported to be a specific opener of MitoKATP channels.18 19 Although the physiological functions of MitoKATP channel are unclear, Szewczyk20 pointed out that the opening of the MitoKATP channel partially compensates the membrane potential, which enables additional protons to be pumped out to form a H+ electrochemical gradient for both ATP synthesis and Ca2+ transport. Mitochondria are known to play at least 2 roles that are essential for cell survival: ATP synthesis and maintenance of Ca2+ homeostasis. During aerobic physiological conditions, a micromolar increase in Ca2+ concentration stimulates the Krebs cycle and NADH redox potential, which is essential for ATP synthesis. High-energy production is essential to support the action of ATP-dependent ion pumps, such as Na+/K+ and Ca2+ pumps,21 to maintain membrane intactness and calcium ion gradients across various cell membranes, including the sarcolemma, sarcoplasmic reticulum, and mitochondria.22 Xu and colleagues.23 proposed that glycolytically derived ATP is functionally coupled to Ca2+ transport by cardiac sarcoplasmic reticulum. Combined, it is possible that the enhancement of ATP production in the preconditioned heart by diazoxide maintains the Ca2+ homeostasis. The action of the electrophoretic K+ uniport and the electroneutral K+/H+ exchange by opening the MitoKATP channel is believed to be primarily responsible for the maintenance of potassium homeostasis within the mitochondrion and the control of intramitochondrial osmotic pressure and mitochondrial volume, which are important in the modulation of metabolic processes.24 Janczcwski and colleagues25 and Wendt-Gallitelli and Isenberg26 reported that Ca2+ transient in the mitochondrial matrix is important for ATP synthesis. A Ca2+ increase within the physiological range stimulates the activity of 3 enzymes: pyruvate dehydrogenase, isocitrate dehydrogenase, and {alpha}-ketoglutarate dehydrogenase. Ca2+-induced increases in NADH redox potential might increase the rate of ATP synthesis.27 28 Ca2+ transient increase also activates Ca2+-dependent PKC isoforms, which leads to cardioprotection. In addition, mitochondria may participate directly in Ca2+ homeostasis by means of separate influx and efflux pathways located within the inner mitochondrial membrane,27 29 which may also regulate mitochondrial volume by opening MitoKATP channels. The total mitochondrial capacity for Ca2+ accumulation is at least several times larger than that of the sarcoplasmic reticulum,30 which suggests a key mitochondrial role for the maintenance of Ca2+ homeostasis during pathological conditions when cytosolic Ca2+ concentration increases substantially. An interesting finding of our study was that verapamil and nifedipine abolished the protective effect of diazoxide. This finding was consistent with our previous report that the protective effect of calcium preconditioning was abolished with verapamil.12 It is possible that diazoxide-induced cardiac protection is also shared by [Ca2+]i-triggered pathways. Diazoxide may also open sarcolemmal channels in smooth muscle.31 However, it may seem to be selective in the heart and liver mitochondria. Also, diazoxide is a potent vasodilator31 and has little effect on the duration of cardiac action potential.9 32 The opening of MitoKATP channels by diazoxide may be a necessary component for higher ATP production to support an increased workload in the heart.10 Thus, a major goal in this study was to preserve as much membrane function and energy production as possible to delay calcium overload and cell damage. Therefore, in light of these functions, it is reasonable to propose that the opening of MitoKATP channels by diazoxide elicits a unique cardiac protection by delaying Ca2+ overload injury.

Role of PKC on the Activation of the MitoKATP Channel by Diazoxide and Its Cardioprotection
PKC is a key enzyme in the regulation of signal transduction and cell growth and differentiation in many cell types.33 34 The role of PKC in preconditioning has been well established by several investigations.35 36 The current study demonstrates that Ca2+ plays an important role in the activation of various second messenger pathways including PKC. This is supported by the current data that the blockade of Ca2+ increase by verapamil inhibits PKC activation and its effect on MitoKATP channels. Thus, it is clear that Ca2+ influx from the exterior of cells is required for PKC and MitoKATP channel activation. The latter observation can only be substantiated by direct measurement of [Ca2+]i transient. However, the participation of Ca2+ in the diazoxide-induced protection may have some relevance because diazoxide is also a known inhibitor of phosphodiesterase,37 38 and this enzyme degrades cAMP.39 Therefore, an increase in cAMP influences cellular functions. It has been reported that inhibition of phosphodiesterase causes an increase in cAMP in myocytes, which, in turn, activates protein kinases that modulate L-type Ca2+ channels such that additional channels open during each depolarization, which leads to an elevated Ca2+ transient.40

The role of Ca2+ in mediating protection against lethal ischemia and Ca2+ overload via PKC has been established by our previous studies2 12 15 41 and by others as well.42 43 Administration of PKC activator PMA produces cardioprotection against Ca2+PD similar to that by diazoxide. This finding was also supported by Sato and colleagues11 who pointed out that the activity of the MitoKATP channel could be regulated by PKC in intact heart cells. Exposure to PMA potentiated and accelerated the effect of diazoxide. The effects of PMA were blocked by the MitoKATP channel blocker 5-HD, which was verified with simultaneous recordings of membrane current and flavoprotein fluorescence. In the latter studies, DeWeille and colleagues44 also demonstrated that stimulation of PKC by the phorbol ester PMA activated the KATP channel. Therefore, the PKC-mediated pathway appears to be important in preconditioning of the isolated rat heart. Because the KATP channel from cardiac mitochondria is {approx}2000 times more sensitive to diazoxide than the channel from cardiac sarcolemma,10 it is reasonable to speculate that PKC activation might phosphorylate both the sarcolemmal KATP and MitoKATP channels.

Diazoxide perhaps stimulates both PKC and MitoKATP channels, thus conferring a greater protection as suggested by increased ATP preservation and better cardiac function. The inhibition of MitoKATP channel-mediated effects by chelerythrine further reinforced the notion that PKC regulates intracellular processes not only by direct phosphorylation of numerous rate-limiting enzyme targets but also by initiating other protein kinase cascades.45 46 Although diazoxide activation of PKC appears to be Ca2+ dependent, there may be cross talk between different second messenger systems, both Ca2+-dependent and -independent, which may act synergistically to induce protection. Given the strategic importance of mitochondria in the cardiac cell, the mitochondrial site of action deserves further molecular characterization.

Translocation of PKC activity from cytosolic to particulate compartments is commonly used as an index of PKC activation.47 We used immunohistochemistry to determine subcellular localization of PKC isoforms. Although this technique primarily provides only qualitative data, the use of isoform-specific anti-PKC antibodies allows the assessment of both isoform-selective activation and compartmentation.48 We confirmed the movement of PKC-{alpha}, PKC-{delta}, PKC-{epsilon}, and PKC-ßI in diazoxide-pretreated hearts. These results are consistent with our previous report that a transient rise in Ca2+ as a result of Ca2+ preconditioning mediated the translocation of PKC-{alpha} to the cell membrane.12 An interesting finding of this study is that PKC-{delta} was predominantly translocated to the mitochondrial sites after diazoxide treatment. Because PKC-{delta}, PKC-{epsilon}, and PKC-ßI are Ca2+-insensitive isoforms, it appears that diazoxide affects both Ca2+-dependent and -independent pathways. The question whether diazoxide increases the [Ca2+]i transient remains unanswered in this study because we did not directly measure intracellular [Ca2+]i during the pretreatment period. However, the diazoxide effect was blocked by verapamil and nifedipine, which suggests Ca2+ influx through these channels by diazoxide treatment. Because no reduction in cellular injury was observed in the hearts subjected to the Ca2+ PD, it is unlikely that myocardium injury is reduced with the concentration of the Ca2+ channel blockers used in this study. The activation of Ca2+-dependent PKC-{alpha} strongly suggests a rise in [Ca2+]i, which was attributed to Ca2+ influx from the extracellular space. Ca2+ could also be released from preloaded mitochondria by opening of MitoKATP channels.49 The translocation of PKC-{alpha} isoform is also consistent with our previous studies with CPC in which a modest increase in [Ca2+]i played an important role in PKC-mediated pathways.12 PKC-{delta} does not require Ca2+ for activation but requires diacylglycerol (DAG) and phosphatidylserine, a component of the plasma membrane.32 48 Transient increase in [Ca2+]i as stated above activates Ca2+-dependent isoforms of PKC and phospholipase C–releasing 1,4,5-inositol triphosphate and DAG, which can stimulate Ca2+-independent isoforms of PKC, such as PKC-{delta} and PKC-{epsilon}.50 The role of DAG in the activation of PKC is supported by our previous studies14 in which hearts were treated with SAG, a precursor of DAG, and by our current study with diazoxide. However, translocation of PKC to sarcolemma or mitochondrial sites was inhibited in hearts after treatment with 5-HD or chelerythrine. Thus it is reasonable to suggest that diazoxide, in addition to its effect on the MitoKATP channel, activates PKC through the Ca2+-mediated pathway. The significance of PKC is further indicated by the translocation of its isoform {epsilon} to the intercalated disks in diazoxide-treated hearts. It is known that weakening of intracellular junctions occurs at intercalated disks during Ca2+ depletion.51 The translocation of PKC-{epsilon} to the intercalated disks in diazoxide-treated hearts may suggest that PKC-{epsilon} might modulate myocardial function through cell-to-cell interaction. In light of these findings, the presence of PKC-{epsilon} in the cell junctions may contribute to effective communication and ion exchange that reduces Ca2+ PD injury.

In summary, we conclude that (1) the opening of the MitoKATP channel by diazoxide is mediated by the PKC signaling pathway; (2) the MitoKATP channel is a key player in Ca2+ preconditioning; and (3) a transient increase in Ca2+ effected by CPC or indirectly by diazoxide is a possible trigger for the activation of PKC.


*    Acknowledgments
 
This study was supported in part by NIH research grants HL-23597 and HL-55678 from the National Heart, Lung, and Blood Institute. The authors thank Atif Ashraf for technical assistance.

Received October 14, 1998; accepted March 4, 1999.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowMeasurement of LDH
up arrowMeasurement of Tissue ATP
up arrowImmunofluorescence Microscopy
up arrowMorphological Examination
up arrowStatistical Analysis
up arrowResults
up arrowDiscussion
*References
 
1. Alto LE, Dhalla NS. Myocardial cation contents during induction of calcium paradox. Am J Physiol. 1979;237:H713–H719.

2. Ashraf M, Suleiman J, Ahmad M. Ca2+ preconditioning elicits a unique protection against the Ca2+ paradox injury in rat heart: role of adenosine: fixed. Circ Res. 1994;74:360–367.[Abstract/Free Full Text]

3. Zimmerman ANE, Hulsmann WC. Paradoxical influence of calcium ions on the permeability of the cell membranes of the isolated rat heart. Nature. 1966;211:646–647.[Medline] [Order article via Infotrieve]

4. Ganote CE. Contraction band necrosis and irreversible myocardial. J Mol Cell Cardiol. 1983;15:67–73.[Medline] [Order article via Infotrieve]

5. Altschuld RA, Ganote CE, Nayler WG, Piper HM. What constitutes the calcium paradox? J Mol Cell Cardiol. 1991;23:765–767.[Medline] [Order article via Infotrieve]

6. Ruigrok TJG. Is an increase of intracellular Na+ during Ca2+ depletion essential for the occurrence of the calcium paradox? J Mol Cell Cardiol. 1990;22:499–501.[Medline] [Order article via Infotrieve]

7. Miyawaki H, Ashraf M. Ca2+ as a mediator of ischemic preconditioning. Circ Res. 1997;80:790–799.[Abstract/Free Full Text]

8. Garlid KD, Paucek P, Yarov-Yarovoy V, Murray HN, Darbenzio RB, D'Alonzo AJ, Lodge NJ, Smith MA, Grover GJ. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels: possible mechanism of cardioprotection. Circ Res. 1997;81:1072–1082.[Abstract/Free Full Text]

9. Liu Y, Sato T, O'Rourke B, Marban E. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation. 1998;97:2463–2469.[Abstract/Free Full Text]

10. Garlid KD, Paucek P, Yarov-Yarovoy V, Sun X, Schindler PA. The mitochondrial KATP channel as a receptor for potassium channel openers. J Biol Chem. 1996;271:8796–8799.[Abstract/Free Full Text]

11. Sato T, O'Rourke B, Marban E. Modulation of mitochondrial ATP-dependent K+ channels by protein kinase C. Circ Res. 1998;83:110–114.[Abstract/Free Full Text]

12. Miyawaki H, Zhou X, Ashraf M. Calcium preconditioning elicits strong protection against ischemic injury via protein kinase C signaling pathway. Circ Res. 1996;79:137–146.[Abstract/Free Full Text]

13. Miller RJ. Multiple calcium channels and neuronal function. Science. 1987;235:46–52[Abstract/Free Full Text]

14. Wang YG, Ashraf M. Activation of {alpha}1-adrenergic receptor during Ca2+ pre-conditioning elicits strong protection against Ca2+ overload injury via protein kinase C signaling pathway. J Mol Cell Cardiol. 1998;30:2423–2435.[Medline] [Order article via Infotrieve]

15. Miyawaki H, Ashraf M. Isoproterenol mimics calcium preconditioning-induced protection against ischemia. Am J Physiol. 1997;272:H927–H936.[Abstract/Free Full Text]

16. Gross GJ, Yao Z, Auchampach JA. Role of ATP-sensitive potassium channels in ischemic preconditioning. In: Przyklenk K, Kloner RA, eds. Ischemic Preconditioning: Concept of Endogenous Cardioprotection. Vol 148. Boston, Mass: Kluwer Academic Publishers. 1994:125–135.

17. Paucek P, Yarov-Yarovoy V, Sun X, Garlid KD. Physiological and pharmacological activators of the mitochondrial KATP channel. Biophys J. 1995;68:A145. Abstract.

18. Inoue I, Nagase H, Kishi K, Higuti T. ATP-sensitive K+ channel in the mitochondrial inner membrane. Nature. 1991;352:244–247.[Medline] [Order article via Infotrieve]

19. Manon S, Guerin M. Evidence for three different electrophoretic pathways in yeast mitochondria: ion specificity and inhibitor sensitivity. J Bioenerg Biomembr. 1993;25:671–678.[Medline] [Order article via Infotrieve]

20. Szewczyk A. The ATP-regulated K+ channel in mitochondria: five years after its discovery. Acta Biochim Pol. 1996;43:713–720.[Medline] [Order article via Infotrieve]

21. Cross HR, Radda GK, Clarke K. The role of Na+/K+ ATPase activity during low flow ischemia in preventing myocardial injury: a 31P, 23Na and 87Rb NMR spectroscopic study. Magn Reson Med. 1995;34:673–685.[Medline] [Order article via Infotrieve]

22. Opie LH. Role of calcium and other ions in reperfusion injury. Cardiovasc Drugs Ther. 1991;5:237–248.

23. Xu KY, Zweier JL, Becker LC. Functional coupling between glycolysis and sarcoplasmic reticulum Ca2+ transport. Circ Res. 1995;77:88–97.[Abstract/Free Full Text]

24. Halestrap AP. The regulation of the matrix volume of mammalian mitochondria in vivo and in vitro and its role in the control of mitochondrial metabolism. Biochim Biophys Acta. 1989;973:355–382.[Medline] [Order article via Infotrieve]

25. Janczcwski AM, Sollot SJ, Spurgeon HA, Lakatta EG. Mitochondrial free Ca2+ in single ventricular myocytes rapidly responds to changes in cytosolic Ca2+. Circulation. 1992;86:1–35.[Abstract/Free Full Text]

26. Wendt-Gallitelli MF, Isenberg G. Total and free myoplasmic calcium during a concentration cycle: X-ray microanalysis in guinea-pig ventricular myocytes. J Physiol (Lond). 1991;435:349–372.[Abstract/Free Full Text]

27. Gunter TE, Pfeiffer DR. Mechanisms by which mitochondria transport calcium. Am J Physiol. 1990;258:C755–C786.[Abstract/Free Full Text]

28. Hunter DR, Haworth RA. Allosteric inhibition of Ca2+ activated hydrophilic channel of the mitochondrial inner membrane by nucleotides. J Membr Biol. 1980;54:231–236.[Medline] [Order article via Infotrieve]

29. Hansford RG. Dehydrogenase activation by Ca2+ in cells and tissues. J Bioenerg Biomembr. 1991;23:823–854.[Medline] [Order article via Infotrieve]

30. Ferrari R. The role of mitochondria in ischemic heart disease. J Cardiovasc Pharmacol. 1996;28(suppl 1):S1–S10.

31. Quast U, Cook NS. In vitro and in vivo comparison of two K+ channel openers, diazoxide and cromakalim, and their inhibition by glibenclamide. J Pharmacol Exp Ther. 1989;250:261–270.[Abstract/Free Full Text]

32. Faivre JF, Findlay I. Effects of tolbutamide, glibenclamide and diazoxide upon action potentials recorded from rat ventricular muscle. Biochim Biophys Acta. 1989;984:1–5.[Medline] [Order article via Infotrieve]

33. Nishizuka Y. Studies and perspectives of protein kinase C. Science. 1986;233:305–312.[Abstract/Free Full Text]

34. Fiedida D, Braun AP, Giles WR. {alpha}1-Adrenoceptors in myocardium: functional aspects and transmembrane signaling mechanisms. Pharmacol Rev. 1993;73:469–487.

35. Mitchell MB, Meng X, Ao LH, Brown JM, Harken AH, Banerjee A. Preconditioning of isolated rat heart is mediated by protein kinase C. Circ Res. 1995;76:73–81.[Abstract/Free Full Text]

36. Cohen MV, Downey JM. Myocardial preconditioning promises to be a novel approach to the treatment of ischemic heart disease. Annu Rev Med. 1996;47:21–29.[Medline] [Order article via Infotrieve]

37. Schultz G, Senft G, W Losert, Sitt R. Biochemische grundlagen der diazoxide-hyperglykamie. Arch Exp Pathol Pharmakol. 1966;253:372–387.

38. Moore PF. The effects of diazoxide and benzothiadiazine diuretics upon phosphodiesterase. Ann N Y Acad Sci. 1968;150:256–260.[Medline] [Order article via Infotrieve]

39. Pagani ED, Buchholz RA, Silver PJ. Cardiovascular cyclic nucleotide phosphodiesterases and their role in regulating cardiovascular function. Basic Res Cardiol. 1992;87:73–86.

40. Tsien RW, Bean BP, Hess P, Lansman JB, Nilius B, Nowycky MC. Mechanisms of calcium channel modulation by ß–adrenergic agents and dihydropyridine calcium agonists. J Mol Cell Cardiol. 1986;18:691–710.[Medline] [Order article via Infotrieve]

41. Miyawaki H, Wang YG, Ashraf M. Oxidant stress with hydrogen peroxide attenuates calcium paradox injury: role of protein kinase C and ATP-sensitive potassium channel. Cardiovasc Res. 1998;37:691–699.[Abstract/Free Full Text]

42. Przyklenk K, Hata K, Kloner RA. Is calcium a mediator of infarct size reduction with preconditioning in canine myocardium? Circulation.. 1997;96:1305–1312.[Abstract/Free Full Text]

43. Meldrum DR, Cleveland JC, Mitchell MB, Sheridan BC, Gamboni-Robertson F, Harken AH, Banerjee A. Protein kinase C mediates Ca2+-induced cardioprotection to ischemia-reperfusion injury. Am J Physiol.. 1996;271:R718–R729.[Abstract/Free Full Text]

44. DeWeille JR, Schmid-Antomarchi H, Fosset M, Lazdunski M. Regulation of ATP-sensitive K+ channels in insulinoma cells: activation by somatostation and protein kinase C and the role of cAMP. Proc Natl Acad Sci U S A. 1989;86:2971–2975.[Abstract/Free Full Text]

45. Houslay MD. `Crosstalk': a pivotal role for protein kinase C in modulating relationships between signal transduction pathway. Eur J Biochem. 1991;195:9–27. Review.[Medline] [Order article via Infotrieve]

46. Moraru II, Jones RM, Popescu LM, Engelman RM, Das DK. Prazosin reduces myocardial ischemia/reperfusion-induced Ca2+ overloading in rat heart by inhibiting phosphoinositide signaling. Biochim Biophys Acta. 1995;1268:1–8.[Medline] [Order article via Infotrieve]

47. Henrich CJ, Simpson PC. Differential acute and chronic response of protein kinase C in cultured neonatal rat heart myocytes to {alpha}1-adrenergic and phorbol ester stimulation. J Mol Cell Cardiol. 1988;20:1081–1085.[Medline] [Order article via Infotrieve]

48. Disatnik MH, Buraggi G, Mochly-Rosen D. Localization of protein kinase C isozymes in cardiac myocytes. Exp Cell Res. 1994;210:287–297.[Medline] [Order article via Infotrieve]

49. Holmuhamedov EL, Jovanovic S, Dzeja PP, Jovanovic A, Terzic A. Mitochondrial ATP-sensitive K+ channels modulate cardiac mitochondrial function. Am J Physiol. 1998;275(pt 2):H1567–H1576.

50. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 1992;258:607–614.[Abstract/Free Full Text]

51. Ashraf M. Correlative studies on sarcolemmal ultrastructure, permeability, and loss of intracellular enzymes in the isolated heart perfused with calcium-free medium. Am J Pathol. 1979;97:411–432.[Abstract]




This article has been cited by other articles:


Home page
Circ. Res.Home page
S. J. Clarke, I. Khaliulin, M. Das, J. E. Parker, K. J. Heesom, and A. P. Halestrap
Inhibition of Mitochondrial Permeability Transition Pore Opening by Ischemic Preconditioning Is Probably Mediated by Reduction of Oxidative Stress Rather Than Mitochondrial Protein Phosphorylation
Circ. Res., May 9, 2008; 102(9): 1082 - 1090.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
R. A. Bouwman, R. J. P. Musters, B. J. van Beek-Harmsen, J. J. de Lange, R. R. Lamberts, S. A. Loer, and C. Boer
Sevoflurane-induced cardioprotection depends on PKC-{alpha} activation via production of reactive oxygen species
Br. J. Anaesth., November 1, 2007; 99(5): 639 - 645.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
V. Garg and K. Hu
Protein kinase C isoform-dependent modulation of ATP-sensitive K+ channels in mitochondrial inner membrane
Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H322 - H332.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Wang, N. Ahmad, B. Wang, and M. Ashraf
Chronic preconditioning: a novel approach for cardiac protection
Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2300 - H2305.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
Y.-S. Park, E.-M. Hur, B.-H. Choi, E. Kwak, D.-J. Jun, S.-J. Park, and K.-T. Kim
Involvement of Protein Kinase C-{varepsilon} in Activity-Dependent Potentiation of Large Dense-Core Vesicle Exocytosis in Chromaffin Cells.
J. Neurosci., August 30, 2006; 26(35): 8999 - 9005.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
G. J. Grover
Mitochondrial ATP-sensitive potassium channels and mitochondrial protein kinase C: sometimes it's good to have a close neighbor
Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1752 - H1753.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. T. Jiang, M. Ljubkovic, Y. Nakae, Y. Shi, W.-M. Kwok, D. F. Stowe, and Z. J. Bosnjak
Characterization of human cardiac mitochondrial ATP-sensitive potassium channel and its regulation by phorbol ester in vitro
Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1770 - H1776.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. Inagaki, E. Churchill, and D. Mochly-Rosen
Epsilon protein kinase C as a potential therapeutic target for the ischemic heart
Cardiovasc Res, May 1, 2006; 70(2): 222 - 230.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. J. Hausenloy and D. M. Yellon
Survival kinases in ischemic preconditioning and postconditioning
Cardiovasc Res, May 1, 2006; 70(2): 240 - 253.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
A. D.T. Costa, K. D. Garlid, I. C. West, T. M. Lincoln, J. M. Downey, M. V. Cohen, and S. D. Critz
Protein Kinase G Transmits the Cardioprotective Signal From Cytosol to Mitochondria
Circ. Res., August 19, 2005; 97(4): 329 - 336.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. Wang, L. Jia, T. Wang, W. Sun, S. Wu, and X. Wang
Endogenous Calcitonin Gene-related Peptide Protects Human Alveolar Epithelial Cells through Protein Kinase C{epsilon} and Heat Shock Protein
J. Biol. Chem., May 27, 2005; 280(21): 20325 - 20330.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Wang, N. Ahmad, M. Kudo, and M. Ashraf
Contribution of Akt and endothelial nitric oxide synthase to diazoxide-induced late preconditioning
Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1125 - H1131.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Mayr, B. Metzler, Y.-L. Chung, E. McGregor, U. Mayr, H. Troy, Y. Hu, M. Leitges, O. Pachinger, J. R. Griffiths, et al.
Ischemic preconditioning exaggerates cardiac damage in PKC-{delta} null mice
Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H946 - H956.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
M. Zaugg, M. C. Schaub, and P. Foex
Myocardial injury and its prevention in the perioperative setting
Br. J. Anaesth., July 1, 2004; 93(1): 21 - 33.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Loubani, A. Hassouna, and M. Galinanes
Delayed preconditioning of the human myocardium: signal transduction and clinical implications
Cardiovasc Res, February 15, 2004; 61(3): 600 - 609.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Gamboa, A. C. Ertl, F. Costa, G. Farley, M. L. Manier, D. L. Hachey, A. Diedrich, and I. Biaggioni
Blockade of Nucleoside Transport Is Required for Delivery of Intraarterial Adenosine Into the Interstitium: Relevance to Therapeutic Preconditioning in Humans
Circulation, November 25, 2003; 108(21): 2631 - 2635.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
W. de Ruijter, R. J.P. Musters, C. Boer, G. J. M. Stienen, W. S. Simonides, and J. J. de Lange
The Cardioprotective Effect of Sevoflurane Depends on Protein Kinase C Activation, Opening of Mitochondrial K+ATP Channels, and the Production of Reactive Oxygen Species
Anesth. Analg., November 1, 2003; 97(5): 1370 - 1376.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
N. Leducq, F. Bono, T. Sulpice, V. e. Vin, P. Janiak, G. L. Fur, S. E. O'Connor, and J.-M. Herbert
Role of Peripheral Benzodiazepine Receptors in Mitochondrial, Cellular, and Cardiac Damage Induced by Oxidative Stress and Ischemia-Reperfusion
J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 828 - 837.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
G. J. Gross and J. N. Peart
KATP channels and myocardial preconditioning: an update
Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H921 - H930.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. C. Zhao and R. C. Kukreja
Protein kinase C-{delta} mediates adenosine A3 receptor-induced delayed cardioprotection in mouse
Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H434 - H441.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. N. Peart and G. J. Gross
Adenosine and opioid receptor-mediated cardioprotection in the rat: evidence for cross-talk between receptors
Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H81 - H89.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Ichinose, H. Yonemochi, T. Sato, and T. Saikawa
Diazoxide triggers cardioprotection against apoptosis induced by oxidative stress
Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H2235 - H2241.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
M. Das, J. E Parker, and A. P Halestrap
Matrix volume measurements challenge the existence of diazoxide/glibencamide-sensitive KATP channels in rat mitochondria
J. Physiol., March 15, 2003; 547(3): 893 - 902.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. Peart, L. Willems, and J. P. Headrick
Receptor and non-receptor-dependent mechanisms of cardioprotection with adenosine
Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H519 - H527.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. M Bell, H. L Maddock, and D. M Yellon
The cardioprotective and mitochondrial depolarising properties of exogenous nitric oxide in mouse heart
Cardiovasc Res, February 1, 2003; 57(2): 405 - 415.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
A. P. Raval, K. R. Dave, D. Mochly-Rosen, T. J. Sick, and M. A. Perez-Pinzon
epsilon PKC Is Required for the Induction of Tolerance by Ischemic and NMDA-Mediated Preconditioning in the Organotypic Hippocampal Slice
J. Neurosci., January 15, 2003; 23(2): 384 - 391.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
Y.-P. Wang, H. Maeta, K. Mizoguchi, T. Suzuki, Y. Yamashita, and M. Oe
Intestinal ischemia preconditions myocardium: role of protein kinase C and mitochondrial KATP channel
Cardiovasc Res, August 15, 2002; 55(3): 576 - 582.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Kudo, Y. Wang, M. Xu, A. Ayub, and M. Ashraf
Adenosine A1 receptor mediates late preconditioning via activation of PKC-delta signaling pathway
Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H296 - H301.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Ohnuma, T. Miura, T. Miki, M. Tanno, A. Kuno, A. Tsuchida, and K. Shimamoto
Opening of mitochondrial KATP channel occurs downstream of PKC-epsilon activation in the mechanism of preconditioning
Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H440 - H447.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
C. P. Baines, J. Zhang, G.-W. Wang, Y.-T. Zheng, J. X. Xiu, E. M. Cardwell, R. Bolli, and P. Ping
Mitochondrial PKC{epsilon} and MAPK Form Signaling Modules in the Murine Heart: Enhanced Mitochondrial PKC{epsilon}-MAPK Interactions and Differential MAPK Activation in PKC{epsilon}-Induced Cardioprotection
Circ. Res., March 8, 2002; 90(4): 390 - 397.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
A. Szewczyk and L. Wojtczak
Mitochondria as a Pharmacological Target
Pharmacol. Rev., March 1, 2002; 54(1): 101 - 127.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
S. P. Goldberg, S. B. Digerness, J. L. Skinner, C. R. Killingsworth, C. R. Katholi, and W. L. Holman
Ischemic preconditioning and Na+/H+ exchange inhibition improve reperfusion ion homeostasis
Ann. Thorac. Surg., February 1, 2002; 73(2): 569 - 574.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. M. Fryer, Y. Wang, A. K. Hsu, H. Nagase, and G. J. Gross
Dependence of delta 1-Opioid Receptor-Induced Cardioprotection on a Tyrosine Kinase-Dependent but Not a Src-Dependent Pathway
J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 477 - 482.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. Mubagwa and W. Flameng
Adenosine, adenosine receptors and myocardial protection: An updated overview
Cardiovasc Res, October 1, 2001; 52(1): 25 - 39.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
Y. Wang, E. Takashi, M. Xu, A. Ayub, and M. Ashraf
Downregulation of Protein Kinase C Inhibits Activation of Mitochondrial KATP Channels by Diazoxide
Circulation, July 3, 2001; 104(1): 85 - 90.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
M. Haller, S. L. Mironov, and D. W. Richter
Intrinsic Optical Signals in Respiratory Brain Stem Regions of Mice: Neurotransmitters, Neuromodulators, and Metabolic Stress
J Neurophysiol, July 1, 2001; 86(1): 412 - 421.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
C. Stamm, I. Friehs, D. B. Cowan, H. Cao-Danh, S. Noria, M. Munakata, F. X. McGowan Jr., and P. J. del Nido
Post-ischemic PKC inhibition impairs myocardial calcium handling and increases contractile protein calcium sensitivity
Cardiovasc Res, July 1, 2001; 51(1): 108 - 121.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
Y. Liu and B. O'Rourke
Opening of Mitochondrial KATP Channels Triggers Cardioprotection : Are Reactive Oxygen Species Involved?
Circ. Res., April 27, 2001; 88(8): 750 - 752.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. M. Fryer, Y. Wang, A. K. Hsu, and G. J. Gross
Essential activation of PKC-{delta} in opioid-initiated cardioprotection
Am J Physiol Heart Circ Physiol, March 1, 2001; 280(3): H1346 - H1353.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Xu, Y. Wang, K. Hirai, A. Ayub, and M. Ashraf
Calcium preconditioning inhibits mitochondrial permeability transition and apoptosis
Am J Physiol Heart Circ Physiol, February 1, 2001; 280(2): H899 - H908.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Wang, J. Cone, and Y. Liu
Dual roles of mitochondrial KATP channels in diazoxide-mediated protection in isolated rabbit hearts
Am J Physiol Heart Circ Physiol, January 1, 2001; 280(1): H246 - H255.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. Huh, G. J. Gross, H. Nagase, and B. T. Liang
Protection of cardiac myocytes via {delta}1-opioid receptors, protein kinase C, and mitochondrial KATP channels
Am J Physiol Heart Circ Physiol, January 1, 2001; 280(1): H377 - H383.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
B. O'Rourke
Pathophysiological and protective roles of mitochondrial ion channels
J. Physiol., November 15, 2000; 529(1): 23 - 36.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
B. O'Rourke
Myocardial KATP Channels in Preconditioning
Circ. Res., November 10, 2000; 87(10): 845 - 855.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
F. Weekers, E. Van Herck, J. Isgaard, and G. Van den Berghe
Pretreatment with Growth Hormone-Releasing Peptide-2 Directly Protects against the Diastolic Dysfunction of Myocardial Stunning in an Isolated, Blood-Perfused Rabbit Heart Model
Endocrinology, November 1, 2000; 141(11): 3993 - 3999.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
G. J. Gross and R. M. Fryer
Mitochondrial KATP Channels : Triggers or Distal Effectors of Ischemic or Pharmacological Preconditioning?
Circ. Res., September 15, 2000; 87(6): 431 - 433.
[Full Text] [PDF]


Home page
Circ. Res.Home page
T. Pain, X.-M. Yang, S. D. Critz, Y. Yue, A. Nakano, G. S. Liu, G. Heusch, M. V. Cohen, and J. M. Downey
Opening of Mitochondrial KATP Channels Triggers the Preconditioned State by Generating Free Radicals
Circ. Res., September 15, 2000; 87(6): 460 - 466.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
E. J. Tanhehco, K. Yasojima, P. L. McGeer, E. G. McGeer, and B. R. Lucchesi
Preconditioning reduces myocardial complement gene expression in vivo
Am J Physiol Heart Circ Physiol, September 1, 2000; 279(3): H1157 - H1165.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. Miura, Y. Liu, H. Kita, T. Ogawa, and K. Shimamoto
Roles of mitochondrial ATP-sensitive K channels and PKC in anti-infarct tolerance afforded by adenosine A1 receptor activation
J. Am. Coll. Cardiol., January 1, 2000; 35(1): 238 - 245.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T. Sato
Signaling in Late Preconditioning : Involvement of Mitochondrial KATP Channels
Circ. Res., December 3, 1999; 85(12): 1113 - 1114.
[Full Text] [PDF]


Home page
Circ. Res.Home page
E. Takashi, Y. Wang, and M. Ashraf
Activation of Mitochondrial KATP Channel Elicits Late Preconditioning Against Myocardial Infarction via Protein Kinase C Signaling Pathway
Circ. Res., December 3, 1999; 85(12): 1146 - 1153.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. Ockaili, V. R. Emani, S. Okubo, M. Brown, K. Krottapalli, and R. C. Kukreja
Opening of mitochondrial KATP channel induces early and delayed cardioprotective effect: role of nitric oxide
Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2425 - H2434.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
Y. Wang, K. Hirai, and M. Ashraf
Activation of Mitochondrial ATP-Sensitive K+ Channel for Cardiac Protection Against Ischemic Injury Is Dependent on Protein Kinase C Activity
Circ. Res., October 15, 1999; 85(8): 731 - 741.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. Ishida, Y. Hirota, C. Genka, H. Nakazawa, H. Nakaya, and T. Sato
Opening of Mitochondrial KATP Channels Attenuates the Ouabain-Induced Calcium Overload in Mitochondria
Circ. Res., November 9, 2001; 89(10): 856 - 858.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, Y.
Right arrow Articles by Ashraf, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, Y.
Right arrow Articles by Ashraf, M.
Related Collections
Right arrow Cell biology/structural biology
Right arrow Cell signalling/signal transduction
Right arrow Ion channels/membrane transport